专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

EP2909201B1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR 有权转让
标题翻译： ACYLAMINOCYCLOALKYLVERBINDUNGEN FOR疾病对调制多巴胺D 3受体应答的治疗
公开(公告)号：EP2909201B1
公开(公告)日：2017-02-22
申请号：EP13785389.1
申请日：2013-10-21
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： HAUPT, Andreas , DINGES, Jürgen , UNGER, Liliane , WICKE, Karsten , VAN WATERSCHOOT, Robert , MITTELSTADT, Scott , DRESCHER, Karla , RELO, Ana
IPC分类号： C07D405/14 , C07D403/04 , C07D405/04 , C07D239/42 , A61K31/506 , A61P25/00
CPC分类号： C07D239/26 , C07D239/42 , C07D403/04 , C07D405/04 , C07D405/14

12. 发明公开

EP2970146A1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR 有权
标题翻译： ACYLAMINOCYCLOALKYLVERBINDUNGEN FOR疾病对调制多巴胺D 3受体应答的治疗
公开(公告)号：EP2970146A1
公开(公告)日：2016-01-20
申请号：EP14710261.0
申请日：2014-03-14
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： HAUPT, Andreas , DINGES, Jürgen , UNGER, Liliane , WICKE, Karsten , VAN WATERSCHOOT, Robert , DRESCHER, Karla , RELO, Ana Lucia
IPC分类号： C07D239/42 , A61K31/506 , A61P25/00
CPC分类号： C07D295/155 , A61K31/496 , C07D239/42 , C07D403/04
摘要： The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH
2 , CH
2 CH
2 , CHFCH
2 and CF
2 CH
2 , R
1 is an oxygen containing cyclic radical selected such as C
3 -C
6 cycloalkyl, which carries one or two oxygen containing radicals selected from the group consisting of OH, C
1 -C
2 -alkoxy, fluorinated C
1 -C
2 -alkoxy, and a carbonyl oxygen,, R
2 is selected from the group consisting of hydrogen, OH and fluorine, R
3a is selected from the group consisting of hydrogen and methyl, R
3b is selected from the group consisting of hydrogen and methyl, R
4 is branched C
4 -C
6 alkyl or branched fluorinated C
4 -C
6 alkyl, and R
5 is inter alia C
1 -C
6 alkyl, fluorinated C
1 -C
3 alkyl, C
1 -C
2 -alkoxy-C
1 -C
4 -alkyl, fluorinated C
1 -C
2 -alkoxy-C
1 -C
4 -alkyl, hydroxy-C
1 -C
4 -alkyl, fluorinated hydroxy-C
1 -C
4 -alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C
3 -C
5 cycloalkyl, fluorinated C
3 -C
5 cycloalkyl, etc.
摘要翻译：本发明涉及新颖的化合物acylaminocycloalkyl，特别是我在和它们的盐和N-氧化物中描述的下式的化合物。这些化合物具有有价值的治疗性质和是合适的，特别是用于治疗疾病并于多巴胺D3受体的调节有反应的。 2 1或2，m是1或，n为A的选自CH 2，CH 2 CH 2，CHFCH2和CF 2 CH 2的选择，R 1是含有氧的环状基团中选择检查作为C3：在式I中，变量具有以下含义 C6环烷基，其携带选自OH中选择的一个或两个氧含有自由基，C1-C2烷氧基，氟化的C 1 -C 2 - 烷氧基，和具有羰基氧，R 2是选自氢由......组成，OH和氟，R 3A为选自氢和甲基中选择，R 3b中选自氢和甲基中选择，R 4是支链的C4-C6烷基或支链氟代C 4 -C 6烷基，而R5是尤其C1-C6烷基，C1-C3氟代烷基，C1-C2烷氧基-C 1 -C 4 - 烷基，氟化的C 1 -C 2 - 烷氧基-C 1 -C 4 - 烷基，羟基-C 1 -C 4 - 烷基，氟化的羟基-C 1 -C 4 - 烷基，氧杂环丁烷基，氟化氧杂环丁基，氧杂环戊基，氧杂环戊基氟化，C3-C5环烷基，氟化的C 3 -C 5环烷基，等等。

13. 发明公开

EP2726479A1 NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A 审中-公开
标题翻译： NEU抑制剂DEN磷酸二酯酶类型10A
公开(公告)号：EP2726479A1
公开(公告)日：2014-05-07
申请号：EP12731416.9
申请日：2012-06-28
申请人： AbbVie Deutschland GmbH & Co KG , AbbVie Inc.
发明人： GENESTE, Hervé , OCHSE, Michael , DRESCHER, Karla , BEHL, Berthold , LAPLANCHE, Loic , DINGES, Jürgen , JAKOB, Clarissa , JANTOS, Katja
IPC分类号： C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , A61K31/44
CPC分类号： C07D471/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要： The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
摘要翻译：本发明涉及新的羧酰胺化合物，含有它们的药物组合物及其在治疗中的用途。该化合物具有有价值的治疗性质，并且特别适用于治疗或控制选自神经障碍和精神疾病的医学病症，用于改善与此类疾病相关的症状并降低此类疾病的风险。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式